Fluvoxamine: a $4 Antidepressant That Reduces COVID 19 Hospitalizations

Roger Seheult, MD of MedCram on how Fluvoxamine Maleate, an inexpensive SSRI medication FDA approved in 1994, was shown to reduce COVID 19 hospitalizations and deaths in a recent randomized placebo controlled trial published in the Lancet. Fluvoxamine (Luvox) was also compared to other medications such as ivermectin, metformin, and hydroxychloroquine in the trial. This is Update 138 in the MedCram Coronavirus Series(This video was recorded on November 1, 2021)TOPICS IN THIS VIDEO INCLUDE:00:00 What is Fluvoxamine, how is it working to treat COVID-19 patients, and how did we get here?00:42 JAMA Study from Nov. 2020: Fluvoxamine vs. Placebo and Clinical Deterioration in Patients with Symptomatic COVID-1901:27 Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI): How do SSRIs work?02:37 History of Fluvoxamine and known side effects03:39 Why would researchers try an SSRI (Fluvoxamine) for COVID-19? Revisiting the role of Reactive Oxygen Species (ROS) and inflammatory factors08:03 Breaking down the data from the smaller JAMA study on Fluvoxamine10:36 Large-scale TOGETHER COVID-19 clinical trials: Is there a medication already in use that could be repurposed for SARS-CoV-2 treatment?12:11 Medications studied in TOGETHER trial: Hydroxychloroquine, Lopinavir/Ritonavir, Metformin, Ivermectin, Doxazosin, Interferon Lambda, and Fluvoxamine13:36 Ivermectin trial data14:07 Fluvoxamine trial data: statistically significant at preventing hospitalization Roger Seheult, MD is the co-founder and lead professor at https://www.medcram.comHe is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine.LINKS / REFERENCES:Fluvoxamine in the treatment of anxiety disorders (PMC) | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2424117/Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial (Lancet) | https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltextWho We Are (Together Trial) | https://www.togethertrial.com/who-we-areThe Sigma-1 Receptor in Cellular Stress Signaling (Frontiers in Neuroscience) | https://www.frontiersin.org/articles/10.3389/fnins.2019.00733/fullAll coronavirus updates are at MedCram.com (including more discussion on the COVID delta variant, fluvoxamine maleate, serotonin syndrome, fluvoxamine 100 mg, vaccine randomized trial and more).SUBSCRIBE TO THE MEDCRAM YOUTUBE CHANNEL:https://www.youtube.com/user/MEDCRAMvideos?sub_confirmation=1Get notified of new videos by hitting the bell iconMEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS:MedCram offers group discounts for students and medical programs, hospitals, and other institutions. Contact us at [email protected] if you are interested.MEDIA CONTACT: Media Contact: [email protected] contact info: https://www.medcram.com/pages/media-contactVideo Produced by Kyle AllredFOLLOW US ON SOCIAL MEDIA:https://www.facebook.com/MedCramhttps://twitter.com/MedCramVideoshttps://www.instagram.com/medcramDISCLAIMER:MedCram medical videos are for medical education and exam preparation, and NOT intended to replace recommendations from your doctor.#COVID19 #SARSCoV2 #Coronavirus